Clinical Trial Update: Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D Tablet in benign prostatic hyperplasia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Benign Prostatic Hyperplasia

Drugs mentioned

• GL2702 GLARS-NF1tablet
• Harnal-D Tablet

Snippet

Sponsor: GL Pharm Tech Corporation | Conditions: Benign Prostatic Hyperplasia | Phase 3 | Status: COMPLETED